Linganisha mbinu

	Uchanganuzi wa Cytometry wa Mtiririko	Kipimo cha Upenyezaji wa Seli za Caco-2	Uundaji wa Kimodelia wa Madhara ya Dawa kwa Idadi ya Watu
Nyanja	Famakolojia	Famakolojia	Famakolojia
Familia	Process / pipeline	Process / pipeline	Process / pipeline
Mwaka wa asili	1976	1989	1992
Mwanzilishi	Leonard Herzenberg	Ingrid Hidalgo	Lewis Sheiner and Stephen Roush
Aina	cell analysis and sorting	absorption screening	dose-response modeling
Chanzo asilia	Herzenberg, L. A., Parks, D., Sahaf, B., Perez, O., Roederer, M., & Herzenberg, L. A. (2002). The history and future of the fluorescence-activated cell sorter and flow cytometry: a view from Stanford. Clinical Chemistry, 48(10), 1819-1827.	Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96(3), 736-749.	Dahlström, B., & Nyberg, L. (1993). Population pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics, 24(1), 45-57.
Majina mbadala	FACS, fluorescence-activated cell sorting, cell analysis	Caco-2 assay, intestinal permeability, ADME screening	PopPD, population PD, hierarchical PD modeling
Zinazohusiana	3	3	3
Muhtasari	Flow cytometry is a laser-based technology for analyzing and sorting individual cells based on fluorescent markers. Developed by Leonard Herzenberg in the 1970s, flow cytometry enables rapid assessment of cell phenotype, drug effects on cell populations, and therapeutic cell characterization in immunology and hematology.	The Caco-2 assay is an in vitro model system using human colon carcinoma cell monolayers to screen drug intestinal permeability. Developed by Hidalgo and colleagues in 1989, Caco-2 cells differentiate into an epithelial barrier resembling intestinal mucosa, enabling rapid assessment of drug absorption potential and identification of transporter-mediated transport.	Population pharmacodynamic (PopPD) modeling integrates pharmacokinetics with individual dose-response relationships across patient populations to characterize drug efficacy and tolerability. Pioneered by Lewis Sheiner and colleagues, PopPD accounts for inter-individual variability in drug effects and enables rational dose optimization and response prediction.